C WorldWide Group Holding A S Grows Position in Heron Therapeutics Inc (HRTX)
C WorldWide Group Holding A S increased its holdings in Heron Therapeutics Inc (NASDAQ:HRTX) by 31.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,600 shares of the biotechnology company’s stock after purchasing an additional 31,600 shares during the quarter. C WorldWide Group Holding A S’s holdings in Heron Therapeutics were worth $2,382,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Perceptive Advisors LLC acquired a new stake in shares of Heron Therapeutics during the third quarter valued at approximately $5,329,000. Vanguard Group Inc. raised its holdings in shares of Heron Therapeutics by 11.8% during the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock valued at $29,036,000 after acquiring an additional 221,362 shares during the period. Rubric Capital Management LP raised its holdings in shares of Heron Therapeutics by 11.8% during the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock valued at $30,685,000 after acquiring an additional 200,000 shares during the period. Chartwell Investment Partners LLC acquired a new stake in shares of Heron Therapeutics during the third quarter valued at approximately $2,340,000. Finally, Janus Henderson Group PLC raised its holdings in shares of Heron Therapeutics by 2.2% during the third quarter. Janus Henderson Group PLC now owns 5,767,495 shares of the biotechnology company’s stock valued at $93,145,000 after acquiring an additional 126,039 shares during the period. Institutional investors and hedge funds own 98.37% of the company’s stock.
Heron Therapeutics Inc (NASDAQ HRTX) opened at $20.50 on Friday. The firm has a market cap of $1,130.00, a P/E ratio of -5.41 and a beta of 1.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics Inc has a 12 month low of $12.70 and a 12 month high of $24.80.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the transaction, the vice president now owns 7,584 shares in the company, valued at approximately $151,680. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 19.93% of the stock is currently owned by corporate insiders.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.